Drug targets for heart failure with preserved ejection fraction: A mechanistic approach and review of contemporary clinical trials

Ravi B. Patel, Sanjiv J. Shah

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.

Original languageEnglish (US)
Pages (from-to)41-63
Number of pages23
JournalAnnual Review of Pharmacology and Toxicology
Volume59
DOIs
StatePublished - Jan 6 2019

Keywords

  • Heart failure with preserved ejection fraction
  • Pathophysiology
  • Pharmacotherapy

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Drug targets for heart failure with preserved ejection fraction: A mechanistic approach and review of contemporary clinical trials'. Together they form a unique fingerprint.

Cite this